FDA & Regulatory Basics


The Food and Drug Administration (FDA) reviews submissions for assurance that the benefits of the product outweigh the perceived risks. The FDA looks to the sponsor to define the nonclinical and clinical study plans, propose specifications, and provide supporting rationale as to why the plan is acceptable. 

Regulatory Basics

MEDICAL PRODUCT TYPES: Most medical products are divided into 3 categories. 

  • Drugs – synthesized chemicals 
  • Devices – mechanical or physical apparatuses  
  • Biologics – extracted or produced from biological materials 

Look at the diagram to familiarize yourself with the regulatory pathway. Consider the questions below regarding your own FDA approval process. 

  • INTERACT: A meeting with the FDA early in product development to obtain informal feedback 
  • IND: Investigational New Drug application (also applies to devices and biologics) 
  • BLA: Biologics License Application 
  • CMC: Chemistry, Manufacturing, and Controls 
  • Pharm/tox: pharmacological and toxicological data (how drugs interact with and potentially harm organisms) 

You may want to research these expedited FDA programs for TEMPS:

  • Regenerative Medicine Advanced Therapy (RMAT) Designation
  • Breakthrough Therapy Designation
  • Fast Track Designation
  • Accelerated Approval Pathway
  • Priority Review Designation 

Questions to Consider: 

  • What regulatory pathway stage are you currently in with your product?  
  • How long do you anticipate it will take to get your product on the market for consumers?  
  • Will your product qualify for any expedited FDA programs? 
  • What support will you need from investors/key partners as you go through the FDA approval process? 
  • What challenges do you anticipate and how do you plan to address them?